The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy.

Journal Article

Deflazacort is the most commonly prescribed corticosteroid for the treatment of Duchenne muscular dystrophy in Canada. We review the long-term experience with deflazacort treatment at two centers in Canada; Montreal and Toronto. Deflazacort has benefitted both cohorts by prolonged ambulation, preserved cardiac and respiratory function, less scoliosis and improved survival. Common side effects in both cohorts include weight gain, decreased height and cataract formation. The Canadian experience supports the use of deflazacort in treating boys with Duchenne muscular dystrophy.

Full Text

Duke Authors

Cited Authors

  • McAdam, LC; Mayo, AL; Alman, BA; Biggar, WD

Published Date

  • May 2012

Published In

Volume / Issue

  • 31 / 1

Start / End Page

  • 16 - 20

PubMed ID

  • 22655512

International Standard Serial Number (ISSN)

  • 1128-2460

Language

  • eng

Conference Location

  • Italy